Another “n=1” PR—this time from AXGT: https://www.globenewswire.com/news-release/2019/12/19/1963193/0/en/Axovant-Provides-Clinical-Program-Update-for-AXO-AAV-GM1-a-Novel-Investigational-Gene-Therapy-for-GM1-Gangliosidosis.html